Ernexa Therapeutics Inc. 8-K

What Happened

• On July 2, 2026, Ernexa Therapeutics Inc. (ERNA) filed a Form 8-K reporting a Regulation FD disclosure: the company made an updated investor presentation available.
• The July 2026 presentation replaces the version posted February 26, 2026, and the updated deck is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: July 2, 2026 (Form 8-K, Regulation FD Disclosure, Item 7.01).
• Presentation: Updated investor presentation titled “Ernexa Therapeutics Investor Presentation – July 2026” (Exhibit 99.1).
• Prior version replaced: presentation posted February 26, 2026.
• No financial results, executive changes, mergers, or other corporate actions were reported in this filing.

Why It Matters

• The update provides investors with the company’s latest investor materials in a public, SEC-filed format—useful for reviewing strategy, pipeline progress, or corporate messaging.
• Because this is a Regulation FD disclosure, it’s intended to ensure material information is shared broadly; however, the filing itself does not report earnings, revenue, or other financial results.